TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26630538
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral medroxyprogesterone acetate (MPA) administered for 10 days per cycle for 6 months
Study: 26630538
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral medroxyprogesterone acetate (MPA) administered daily for 6 months
Study: 22134043
Drug: Haloperidol (2.5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2.5‐10 mg/day)
Study: 16708310
Drug: CRP test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP test (above 50 mg/l)
Study: 22808045
Drug: Heated blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated blood transfusion/fluid infusion
Study: 20479297
Drug: Etanercept, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept, 50 mg, SC administered twice weekly for 12 weeks
Study: 18184958
Drug: HES therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES therapy
Study: 15844469
Drug: DHEA replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA replacement (50 mg/day)
Study: 15318461
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (1 microg kg(‐1))
Study: 15318461
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (3 microg kg(‐1))
Study: 15318461
Drug: Remifentanil (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (any dose)
Study: 11386092
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% plus 0.5 microgram ml‐1 sufentanil
Study: 8128328
Drug: Endoscopic thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic thrombin injections in actively bleeding patients (group II, N = 94)
Study: 8128328
Drug: Endoscopic thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic thrombin injections in non-bleeding visible vessels (group A, N = 25)
Study: 8128328
Drug: No primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No primary endoscopic treatment in non-bleeding visible vessels (group B, N = 25)
Study: 26731401
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between treatment and control groups during the intervention period.
Study: 12572380
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy + QHBDY
Study: 8556909
Drug: Mifepristone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 150 mg single dose treatment
Study: 8556909
Drug: Early pregnant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pregnant cervix before treatment
Study: 2242521
Drug: Nifedipine-ISDN combination
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine-ISDN combination
Study: 577428
Drug: Benzopyrone compound
Normalized name: benzopyrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyrone compound Venalot (2 depot tablets b.d.)
Study: 19014751
Drug: Divalproex (500‐2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (500‐2500 mg/day)
Study: 16292090
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 500 mg twice daily
Study: 12785003
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (40 microg/kg/min)
Study: 1667753
Drug: Pyrophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrophosphate dentifrice (F-Antibelag Gel + K4P2O7/Na4P2O7)
Study: 1667753
Drug: Placebo (F-Antibelag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (F-Antibelag Gel)
Study: 31262153
Drug: Maximal strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal strength training (twice a week for 3 months)
Study: 31262153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prescribed treatment without strength training)
Study: 24623024
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IT) with a target blood glucose range of 4.4‐6.1 mmol/L
Study: 24623024
Drug: Intermediate insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate insulin therapy (IT) with a target blood glucose range of 7.7‐10.0 mmol/L
Study: 17941876
Drug: Nateglinide monotherapy
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide monotherapy (120 mg before meals)
Study: 17941876
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg before meals) + Metformin (up to 1000 mg bid)
Study: 17941876
Drug: Glyburide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (up to 5 mg bid) + Metformin (up to 1000 mg bid)
Study: 12802092
Drug: Tongue strengthening
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue strengthening exercises using the Iowa Oral Performance Instrument
Study: 11105936
Drug: Cocaine (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.9 mg/kg)
Study: 9065557
Drug: Hu-related molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hu-related molecules of 35 to 41 kDa detected in the membrane of small-cell lung cancers and neuroblastomas using immunofluorescence, absorption assays, Western blotting on membrane fractions, and surface biotinylation.
Study: 8452191
Drug: Amoxicillin 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3,000 mg
Study: 2878173
Drug: Warfarin started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin started within 3 days of heparin (group S)
Study: 2878173
Drug: Warfarin started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin started after 7 days of heparin (group L)
Study: 29878341
Drug: DFN-02 (sumatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-02 (sumatriptan 10 mg with DDM)
Study: 12699521
Drug: Ketamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.1 mg kg(‐1) i.m. premedication
Study: 11033836
Drug: rhIL-11 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 in combination with G-CSF (filgrastim)
Study: 9193196
Drug: High-dose quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose quetiapine fumarate (<= 750 mg/d)
Study: 9193196
Drug: Low-dose quetiapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quetiapine fumarate (<= 250 mg/d)
Study: 28030431
Drug: LCZ696/amlodipine (200/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696/amlodipine (200/5 mg/day)
Study: 15803442
Drug: Thrombolytic drug
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic drug regimens
Study: 12296638
Drug: Tirilazad treatment
Normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad treatment in patients with TBI
Study: 7637174
Drug: Ulinastatin (12,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (12,000 units.kg‐1) administered 15 min after starting CPB in the bubble oxygenator group
Study: 73313
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily for 3 days every second week)
Study: 30565718
Drug: High-protein oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein oral nutrition supplement (S-ONS)
Study: 17185047
Drug: Colistin dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin dry powder inhalation (25 mg)
Study: 17185047
Drug: Nebulised colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised colistin (158 mg)
Study: 15584584
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (remifentanyl and propofol)
Study: 15584584
Drug: Inhaled anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anaesthesia (isoflurane and fentanyl)
Study: 11466098
Drug: Daily pacifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pacifier use (observational analysis)
Study: 8301443
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at doses from 5 to 80 ppm
Study: 2732981
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg metronidazole (two sponges per day for two days)
Study: 2732981
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg metronidazole (one sponge per day for three days)
Study: 30940189
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S‐1 [80‐120 mg] on days 1‐10, repeated every 14 days)
Study: 30940189
Drug: S‐1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 monotherapy (80‐120 mg/day on days 1‐14, repeated every 21 days)
Study: 28081543
Drug: S‐1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 monotherapy
Study: 25011019
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (85,300 IU weekly for 1 year)
Study: 24682069
Drug: Aleglitazar 150
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 µg daily
Study: 19956761
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g) given at 16-24 and 28-32 weeks gestation
Study: 17725940
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg orally 3 times, beginning the day before ERCP until the night after the procedure.
Study: 17725940
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive medication (Control group).
Study: 17725940
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg orally.
Study: 16095435
Drug: Ceftriaxone sodium
Normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone sodium as empiric therapy with physician notification
Study: 7744150
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei preparation (BLP)
Study: 7057051
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (Fluocinonide)
Study: 30790396
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC)
Study: 23916044
Drug: Retigabine/ezogabine (600-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine/ezogabine (600-1200 mg/d)
Study: 19813275
Drug: Amifostine (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent)
Study: 14984396
Drug: Citalopram (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (mean dose 26.3 mg)
Study: 11679464
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg b.i.d. for 6 months
Study: 11679464
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 6 months
Study: 23832078
Drug: ONS (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS (Oral Nutritional Supplement)
Study: 23832078
Drug: ONS800 (ONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS800 (ONS plus 800 mg beta-alanine)
Study: 23832078
Drug: ONS1200 (ONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS1200 (ONS plus 1200 mg beta-alanine)
Study: 19545479
Drug: Anger treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anger treatment program
Study: 16434603
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy and cognitive behavioral therapy
Study: 15541080
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed combination therapy for diabetic ulcers with exposed bones (n = 11)
Study: 15541080
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for diabetic ulcers without exposed bones (n = 8)
Study: 11384563
Drug: Emedastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 0.05% eye drops, administered twice daily for 6 weeks
Study: 11384563
Drug: Levocabastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05% eye drops, administered twice daily for 6 weeks
Study: 7967703
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated wholly with Western drugs
Study: 21346162
Drug: Mood-elevating suggestion
Normalized name: RELACORE STRESS REDUCER/MOOD ELEVATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-elevating suggestion before ketamine administration
Study: 6344034
Drug: Fendosal 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendosal 200 mg
Study: 6344034
Drug: Fendosal 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendosal 400 mg
Study: 26440233
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental 1.5 mg/kg
Study: 17342995
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional drug (Blank group)
Study: 15112871
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 gr. i.v. preoperative and every 8 hrs. during the first day (3 doses) followed by ciprofloxacin 250 mg. oral every 12 hrs until catheter removal.
Study: 15112871
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 gr. i.v. preoperative and at 8 hrs postoperative (2 doses) followed by nitrofurantoin 100 mg. oral every night until catheter removal.
Study: 29092739
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (200 mg elemental iron/day)
Study: 22066459
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (0.6 mL x kg(‐1) and physiological saline 100 mL)
Study: 22066459
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (equal volume to Shenmai injection)
Study: 19628730
Drug: 1 spray
Normalized name: Hygiene 1 Spray Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 spray of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Study: 19628730
Drug: 2 sprays
Normalized name: fentanyl 1,200 mcg (600 mcg/spray, 2 sprays) SUBLINGUAL SPRAY, NON-AEROSOL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Study: 19628730
Drug: 3 sprays
Normalized name: tetracaine/benzocaine/butamben 2 %-14 %-2 % (200 mg/3 sprays) TOPICAL AEROSOL, METERED SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sprays of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Study: 17019520
Drug: Maxmarvil (calcitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxmarvil (calcitriol 0.5 mug and alendronate 5 mg)
Study: 10949718
Drug: Actarit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actarit treatment for 24 weeks in group I (stages I and II)
Study: 10949718
Drug: Actarit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actarit treatment for 24 weeks in group II (stages III and IV)
Study: 10949718
Drug: Actarit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actarit treatment in group I
Study: 10949718
Drug: Actarit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actarit treatment in group II
Study: 8767154
Drug: Heparin calcine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin calcine
Study: 1351053
Drug: Oral repeat‐action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeat‐action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4‐16 mg at bedtime
Study: 4096741
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine retard-tablet (Pidilat retard)
Study: 4096741
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine retard-tablet (marketed formulation)
Study: 24989685
Drug: Gadolinium injection
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium injection (0.2 mmol/kg)
Study: 2334616
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg kg‐1
Study: 2334616
Drug: Bupivacaine 2
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2 mg kg‐1 with adrenaline 1:200,000
Study: 26145190
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid (TXA) 3 g plus diluted epinephrine (DEP) 0.25 mg
Study: 26145190
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tranexamic acid (TXA) 3 g alone
Study: 23307164
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml
Study: 21930354
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone spray for 26 weeks
Study: 18281145
Drug: 10mg vardenafil
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg vardenafil twice daily
Study: 2691477
Drug: Amoxycillin/clavulanate (iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (iv 100 mg/kg/day followed by oral 50 mg/kg/day)
Study: 2691477
Drug: Benzylpenicillin (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin (100,000 IU/kg/day) + netilmicin (5 mg/kg/day) + metronidazole (30 mg/kg/day) (iv followed by oral metronidazole 30 mg/kg/day)
Study: 30802200
Drug: Ertugliflozin 2.5
Normalized name: ertugliflozin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 2.5 mg BID
Study: 30802200
Drug: Ertugliflozin 7.5
Normalized name: ertugliflozin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 7.5 mg BID
Study: 396660
Drug: i.v. pirenzepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pirenzepine infusion (16 mg plus 2 mg/h for 2 hours)
Study: 29619965
Drug: HIV-infected women
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected women receiving curative chemoradiation therapy (CRT)
Study: 29619965
Drug: HIV-uninfected women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-uninfected women receiving curative chemoradiation therapy (CRT)
Study: 24720679
Drug: ABT‐450/r-ombitasvir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐450/r-ombitasvir and dasabuvir with ribavirin (150 mg of ABT‐450, 100 mg of ritonavir, 25 mg of ombitasvir, 250 mg dasabuvir twice daily, and 1000 or 1200 mg ribavirin daily)
Study: 22948032
Drug: Monovo® Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovo® Cream (new formulation of mometasone furoate with 33% water content)
Study: 22948032
Drug: Ecural® Fettcreme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecural® Fettcreme (commercially available fatty cream of mometasone furoate)
Study: 9619531
Drug: Alpha‐methyl‐para‐tyrosine (AMPT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐methyl‐para‐tyrosine (AMPT), 5 x 1 g doses over 26 hours
Study: 9619531
Drug: Promethazine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (active placebo), 5 x 50 mg doses over 26 hours
Study: 7663867
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine plus tenoxicam (20 mg, i.v.)
Study: 31319484
Drug: I2 (5
Normalized name: Iodine-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: I2 (5 mg/day) before surgery for 7-35 days
Study: 23984806
Drug: Canrenone 50
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 50 mg/day for 3 months, then 50 mg b.i.d. until the end of the study
Study: 17092457
Drug: Pediatric constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric constraint‐induced therapy involving constraint of the functional upper extremity and intensive therapy with the hemiparetic upper extremity
Study: 17092457
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical and occupational therapy
Study: 8408933
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (10 micrograms/kg)
Study: 8408933
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (100 micrograms, twice)
Study: 29237386
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ω‐3 fatty acids and nano‐curcumin
Study: 21047922
Drug: Intralipid/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid/heparin infusion with 1 mU/min · kg euglycemic insulin clamp
Study: 18496366
Drug: Insulin-mediated euglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-mediated euglycemia (mean blood glucose, 5.8 +/- 0.4 mmol/L)
Study: 18496366
Drug: Moderate hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hyperglycemia (mean blood glucose, 9.6 +/- 0.6 mmol/L)